In vivo clot lysis of human thrombus with intravenous abciximab immunobubbles and ultrasound

Alonso, Angelika; Dempfle, Carl-Erik; Martina, Alberto Della; Stroick, Mark; Fatar, Marc; Zohsel, Katrin; Allémann, Éric; Hennerici, Michael G.; Meairs, Stephen

doi:10.1016/j.thromres.2008.11.019

Cited by 61 publications

(46 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vivo thrombolysis study was performed according to the procedure reported earlier by Alonso et al (2009), with modifications. Wistar rats weighing between 450 and 550 g were anaesthetized with pentobarbitol (100 mg/kg).…”

Section: In Vivo Thrombolysis Studymentioning

confidence: 99%

Development and characterization of highly selective target-sensitive liposomes for the delivery of streptokinase: in vitro/in vivo studies

et al. 2014

View full text Add to dashboard Cite

Streptokinase is one of the most commonly used thrombolytic agents for the treatment of thromboembolism. Short half-life of the streptokinase requires administration of higher dose which results in various side effects including systemic haemorrhage due to activation of systemic plasmin. To increase the selectivity of the streptokinase and hence to reduce side effects, various novel carriers have been developed. Among these carriers, liposomes have been emerged as versatile carrier. In the present study, highly selective target-sensitive liposomes were developed and evaluated by in vitro and in vivo studies. Prepared liposomes were found to release streptokinase in vitro following binding with activated platelets. Intravital microscopy studies in thrombosed murine model revealed higher accumulation of liposomes in the thrombus area. In vivo thrombolysis study was performed in the human clot inoculated rat model. Results of the study showed that target-sensitive liposomes dissolved 28.27 ± 1.56% thrombus as compared to 17.18 ± 1.23% of non-liposomal streptokinase. Further, it was also observed that target-sensitive liposomes reduced the clot dissolution time as compared to streptokinase solution. Studies concluded that developed liposomes might be pragmatic carriers for the treatment of thromboembolism.

show abstract

Section: In Vivo Thrombolysis Studymentioning

confidence: 99%

Development and characterization of highly selective target-sensitive liposomes for the delivery of streptokinase: in vitro/in vivo studies

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Platelets, which exist in high concentrations on the surface of thrombi, can be targeted by conjugating a glycoprotein (GP) IIb/IIIa receptor inhibitor to the delivery vesicle [200][201][202][203][204]. Investigations implementing this targeting strategy show enhanced thrombolysis in the presence of a thrombolytic and targeted microbubbles exposed to US.…”

Section: Drug Targetingmentioning

confidence: 99%

Ultrasound-Mediated Drug Delivery for Cardiovascular Disease

Holland

2017

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

Introduction-Ultrasound (US) has been developed as both a valuable diagnostic tool and a potent promoter of beneficial tissue bioeffects for the treatment of cardiovascular disease. These effects can be mediated by mechanical oscillations of circulating microbubbles, or US contrast agents, which may also encapsulate and shield a therapeutic agent in the bloodstream. Oscillating microbubbles can create stresses directly on nearby tissue or induce fluid effects that effect drug penetration into vascular tissue, lyse thrombi or direct drugs to optimal locations for delivery.Areas covered-The present review summarizes investigations that have provided evidence for US-mediated drug delivery as a potent method to deliver therapeutics to diseased tissue for cardiovascular treatment. In particular, the focus will be on investigations of specific aspects relating to US-mediated drug delivery, such as delivery vehicles, drug transport routes, biochemical mechanisms and molecular targeting strategies.Expert opinion-These investigations have spurred continued research into alternative therapeutic applications, such as bioactive gas delivery and new US technologies. Successful implementation of US-mediated drug delivery has the potential to change the way many drugs are administered systemically, resulting in more effective and economical therapeutics, and lessinvasive treatments.

show abstract

“…26 Importantly, ligand targeting of bubbles with abciximab improves the effectiveness of lysis with US. 27 Entrapment of tPA into liposomes can also improve the efficacy of thrombolysis 28 -33 through cavitational effects and acoustic radiation force. 34 Recent work suggests that tPAloaded echogenic liposomes are superior to microbubbles for clot lysis with US.…”

Section: Targeted Sonothrombolysismentioning

confidence: 99%